bismuth subcitrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4355 57644-54-9

Description:

MoleculeDescription

Synonyms:

  • bismuth subcitrate
  • bismuth tripotassium dicitrate
  • bismuth subcitrate potassium
contains tripotassium di-citratobismuthate used in gastric & duodenal ulcer therapy; do not confuse with colloidal bismuth subnitrate
  • Molecular weight: 704.47
  • Formula: C12H10BiK3O14
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 140.62
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
0.48 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Sept. 28, 2006 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug eruption 147.86 74.05 31 233 35376 90592807

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug eruption 88.73 74.44 19 112 23056 42598148

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug eruption 228.67 61.01 50 368 53609 110535272
Pruritus 89.13 61.01 43 375 581517 110007364

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A02BD08 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Combinations for eradication of Helicobacter pylori
ATC A02BX05 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
MeSH PA D000863 Antacids
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000897 Anti-Ulcer Agents
MeSH PA D005765 Gastrointestinal Agents
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:49201 anti-ulcer drug
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

A02BD Combinations for eradication of Helicobacter pylori 13 drugs
amoxicillinclarithromycinesomeprazolelansoprazolelevofloxacinmetronidazoleomeprazolepantoprazolerabeprazolerifabutintetracyclinetinidazole show all 13 →
A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) 15 drugs
acetoxolonealginic acidbismuth subnitratecarbenoxolonegefarnateirsogladinemethiosulfonium chloridepirenzepineproglumiderebamipidesucralfatesulglicotide show all 15 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Duodenal Ulcer due to H. Pylori indication
Alcoholism contraindication 7200002
Lowered convulsive threshold contraindication 19260006
Alcohol intoxication contraindication 25702006
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Disorder of brain contraindication 81308009 DOID:936
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Seizure disorder contraindication 128613002
Non-infective meningitis contraindication 230155003
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Peripheral nerve disease contraindication 302226006
Neutropenic disorder contraindication 303011007 DOID:1227
Pseudomembranous enterocolitis contraindication 397683000
Breastfeeding (mother) contraindication 413712001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4026166 VUID
N0000179322 NUI
D09739 KEGG_DRUG
4026166 VANDF
C0106556 UMLSCUI
CHEBI:749392 CHEBI
CHEMBL1201186 ChEMBL_ID
CHEMBL1744033 ChEMBL_ID
C002791 MESH_SUPPLEMENTAL_RECORD_UI
HS813P8QPX UNII
10101269 PUBCHEM_CID
DB09275 DRUGBANK_ID
1294617 RXNORM
23879 MMSL
d04952 MMSL
003773 NDDF
396007005 SNOMEDCT_US
420020009 SNOMEDCT_US
735064002 SNOMEDCT_US
737682001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 3 49884-151 CAPSULE 140 mg ORAL ANDA 27 sections
Bismuth subcitrate potassium, Metronidazole, Tetracycline hydrochloride HUMAN PRESCRIPTION DRUG LABEL 3 50742-283 CAPSULE 140 mg ORAL ANDA 20 sections
Pylera HUMAN PRESCRIPTION DRUG LABEL 3 54868-6151 CAPSULE 140 mg ORAL NDA 27 sections
PYLERA HUMAN PRESCRIPTION DRUG LABEL 3 61269-380 CAPSULE 140 mg ORAL NDA 32 sections
PYLERA HUMAN PRESCRIPTION DRUG LABEL 3 61269-381 CAPSULE 140 mg ORAL NDA 31 sections
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 3 61269-385 CAPSULE 140 mg ORAL NDA 32 sections
Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 3 61269-386 CAPSULE 140 mg ORAL NDA authorized generic 31 sections